These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22491963)

  • 1. Treating ADHD with agomelatine.
    Niederhofer H
    J Atten Disord; 2012 May; 16(4):346-8. PubMed ID: 22491963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine treatment with adolescents with ADHD.
    Niederhofer H
    J Atten Disord; 2012 Aug; 16(6):530-2. PubMed ID: 22668524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial.
    Salardini E; Zeinoddini A; Kohi A; Mohammadi MR; Mohammadinejad P; Khiabany M; Shahriari M; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):513-9. PubMed ID: 27286139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of a new antidepressant : agomelatine].
    Mocaër E; Delalleau B; Boyer PA; de Bodinat C
    Med Sci (Paris); 2005 Oct; 21(10):888-93. PubMed ID: 16197911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
    Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
    Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
    Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
    Srinivasan V; De Berardis D; Shillcutt SD; Brzezinski A
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats.
    Souza LC; Martynhak BJ; Bassani TB; Turnes JM; Machado MM; Moura E; Andreatini R; Vital MABF
    Physiol Behav; 2018 May; 188():298-310. PubMed ID: 29458117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D; Baghai TC; Möller HJ
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.